VivoSim Labs (NASDAQ: VIVS) has announced the availability of an AI prediction tool leveraging its NAMkind intestinal models to accurately predict the potential of a drug to cause diarrhea in patients, eliminating reliance on animal models.
According to VivoSim, the tool integrates its proprietary NAMkind ileum and colon tissues with advanced machine learning analytics to identify drug induced disruptions to intestinal epithelial integrity and function. Tissue-based assay data is used to train an AI predictive model in a process the company has named VitroSense.
In a statement, Keith Murphy, executive chairman of VivoSim, commented, “The high biological fidelity of NAMkind models allows us to generate data in line with what is seen in humans. By using that high-quality data to train AI models, we get much more accurate predictions. You’ve heard of “garbage in, garbage out”, but our models are the opposite: Golden raw data from NAMkind tissue assays is fed to the VitroSense model and spun into solid gold predictions for our clients’ compounds.”
